|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Safety, tolerability, phar- macodynamics, and pharmacokinetics of rivaroxaban-an oral, di- rect Factor Xa inhibitor-are not affected by aspirin 显示文摘 | Kubitza D Becka M Mueck W | 2006 | J Clin Pharmacol2006，46，9： | 1 |
| 2 | No interaction between the novel oral direct factor Xa inhibitor BAY 59-7939 and digoxin 显示文摘 | Kubitza D Mueck W Becka M | 2006 | J Clin Phann2006，46，3： | 1 |
| 3 | Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral direct factor Xa inhibitor in healthy subjects显示文摘 | Mueck W Beeka M Kubitza D | | 0，，： | 1 |
| 4 | Horseshoe kidneys:a 40-year experience显示文摘 | PITTS W R Jr MUECKE E C | 1975 | J Urol1975，113，： | 1 |
| 5 | Safety, tolerabil- ity, pharmacodynamics, and pharmacokinetics of rivaroxa- ban--an oral, direct factor Xa inhibitor--are not affected by aspirin 显示文摘 | KUBITZA D BECKA M MUECK W | 2006 | J Clin Pharmacol2006，46，9： | 1 |
| 6 | Austrian Moder- ate Altitude Studies (AMAS): benefits of exposure to moderate alti- tudes (1,500-2,500 m) 显示文摘 | Schobersberger W Leichtfried V Mueck M | 2010 | Sleep Breath2010，14，3： | 1 |
| 7 | Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban -- an oral direct factor Xa inhibitor -- in healthy subjects 显示文摘 | Mueck W Becka M Kubitza D | 2007 | Int J Clin Pharmacol Ther2007，45，33： | 1 |
| 8 | Rivaroxaban(BAY 59-7939)-an oral,direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen 显示文摘 | Kubitza D Becka M Mueck W | 2007 | Br J Clin Pharmacol2007，63，4： | 1 |
| 9 | Rivaroxaban (BAY 59-7939)-anoral,direct factor xa inhibitor-has no clinically relevant interaction with naproxen显示文摘 | Kubitza D Becka M Mueck W | 2007 | Br J Clin Pharmaeol2007，63，4： | 1 |
| 10 | The oral direct factor Xa inhibitor BAY 59-7939 does not prolong the QTc in- terval 显示文摘 | Kubitza D Mueck W Becka M | 2006 | J Clin Pharm2006，46，8： | 1 |
| 11 | Formation fines and factors controlling their movement in porous media显示文摘 | | 1979 | JPT1979，，2： | 1 |
| 12 | Dose-escalation study of the pharmacokinetics and pharmaeodynamics of rivaroxaban in heahhy elderly subjects显示文摘 | Kubitza D Becka M Roth A Mueck W | 2008 | Current Med Res Opin2008，24，： | 1 |
| 13 | Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban显示文摘 | Mueck W Stampfuss J Kubitza D | 2014 | Clin Pharmacokinet2014，53，1： | 1 |
| 14 | Rivaroxaban and other novel oral anticoagulants:pharmacokinetics in healthy subjects,specific patient populations and relevance of coagulation monitoring显示文摘 | Mueck W Schwers S Stampfuss J | 2013 | Thromb J2013，11，1： | 1 |
| 15 | Rivaroxaban and other novel oral anticoagulants:pharmacokinetics in healthy subjects,specific patient populations and relevance of coagulation monitoring显示文摘 | Mueck W Schwers S Stampfuss J | 2013 | Thromb J2013，11，1： | 1 |
| 16 | In-situ trace gas analysis using high-frequency modulation spectroscopy with tunable diode la-sers显示文摘 | WERLE P W MUECKE | | 0，，： | 1 |
| 17 | Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in healthy subjects显示文摘 | MUECK W BECKA M KUBITZA D | 2007 | Int J Clin Pharmacol Ther2007，45，6： | 1 |
| 18 | Horseshoe kidneys: a 40-year experience 显示文摘 | Pitts W R Muecke E C | 1975 | J Urol1975，113，6： | 1 |
| 19 | Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral direct factor Xa inhibitor-in healthy subjects显示文摘 | Mueck W Becka M Kubitza D | 2007 | Int J Clin Pharmacol Ther2007，45，： | 1 |
| 20 | Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban an oral, direct factor Xa inhibitor are not affected by aspirin 显示文摘 | Kubitza D Becka M Mueck W | 2006 | J Clin Pharmacol2006，46，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员